Acquired by AstraZeneca in Mar 2024
ICVX - Icosavax, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Seattle,
United States
Type: Equity
ICVX price evolution
ICVX
| (in millions $) | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $63.2 | $155.07 | $49.34 | $58.85 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $235.3 | $251.7 | $202.17 | $223.91 |
| Long term investments | ||||
| Property, plant & equipment | $14.4 | $15.2 | $15.39 | $14.76 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $251.3 | $269.03 | $219.67 | $238.68 |
| Current liabilities | ||||
| Accounts payable | $1.2 | $1.55 | $1.61 | $2.89 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $13 | $15.01 | $12.9 | $13.79 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $18.9 | $21.3 | $19.59 | $20.52 |
| Shareholders' equity | ||||
| Retained earnings | -$258.9 | -$236.88 | -$210.39 | -$185.83 |
| Other shareholder equity | -$0.07 | -$0.06 | -$0.4 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $58.85 | $279.08 | $13.11 | $23.08 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $223.91 | $286.55 | $16.16 | $23.29 |
| Long term investments | ||||
| Property, plant & equipment | $14.76 | $1.08 | $0.01 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $238.68 | $287.63 | $16.17 | $23.29 |
| Current liabilities | ||||
| Accounts payable | $2.89 | $3.9 | $1.92 | $0.8 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $13.79 | $9.24 | $5.83 | $1.22 |
| Long term debt | $4.95 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $20.52 | $9.41 | $12.81 | $1.47 |
| Shareholders' equity | ||||
| Retained earnings | -$185.83 | -$94.07 | -$27.1 | -$8.24 |
| Other shareholder equity | -$0.4 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $25.28 | $28.96 | $26.52 | $25.13 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $3.23 | $2.46 | $1.96 | $1.52 |
| Net income | ||||
| Net income | -$22.04 | -$26.5 | -$24.56 | -$23.61 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.58 | $7.8 | $1.62 | |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $95.64 | $73.67 | $20.33 | $5.4 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $3.3 | -$0.36 | -$0.14 | $0.1 |
| Net income | ||||
| Net income | -$91.76 | -$66.97 | -$18.85 | -$5.97 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$4.81 | $67.85 | $12.03 | -$169.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $67.98 | $68.19 | $0.12 | $10.31 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $3.33 | $95.17 | -$9.5 | -$220.82 |
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$169.45 | -$1.01 | -$0.01 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $10.31 | $304.77 | $6.64 | $26.74 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$220.82 | $265.22 | -$7.58 | $22.17 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 50.10M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$96.71M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 1.26 |
| EPS | -$1.93 |
|---|---|
| ROA | -39.53% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 18.10 |
| Quick ratio | N/A |